Research Article
Prognostic Utility of Vitamin D in Acute Coronary Syndrome Patients in Coastal Norway
Table 1
Baseline characteristics of the total population arranged according to the quartiles of 25(OH)D.
| | Characteristics (%) | Quartiles of 25(OH)D | value | | Q1 | Q2 | Q3 | Q4 |
| | 25(OH)D (nmol/L) | 30.5 ± 5.9 | 45.2 ± 3.4 | 56.7 ± 3.6 | 78.6 ± 13.2 | <0.001 | | 25(OH)D (ng/mL) | 12.2 ± 2.4 | 18.1 ± 1.4 | 22.7 ± 1.4 | 31.4 ± 5.3 | <0.001 | | Age, years | 68.9 ± 16.1 | 69.4 ± 15.6 | 70.7 ± 13.2 | 69.3 ± 12.4 | 0.591 | | Male, (%) | 120 (55.8) | 138 (64.2) | 127 (58.8) | 140 (65.1) | 0.150 | | Smoking status, (%) | | | | | 0.110 | | Current smoker, (%) | 71 (33.0) | 58 (27.0) | 46 (21.3) | 52 (24.2) | | | Past smoker, (%) | 65 (30.2) | 78 (36.3) | 83 (38.4) | 87 (40.5) | | | Never smoked, (%) | 79 (36.7) | 79 (36.7) | 87 (40.3) | 76 (35.3) | | | Angina pectoris, (%) | 93 (43.3) | 90 (41.9) | 100 (46.3) | 93 (43.3) | 0.820 | | CHF, (%) | | | | | | | Killip Class 2–4 | 84 (39.1) | 48 (22.3) | 52 (24.1) | 48 (22.3) | <0.001 | | History of previous MI, (%) | 82 (38.1) | 69 (32.1) | 71 (32.9) | 66 (30.7) | 0.382 | | CABG, (%) | 22 (10.2) | 17 (7.9) | 26 (12.0) | 22 (10.2) | 0.564 | | PCI, (%) | 18 (8.4) | 21 (9.8) | 25 (11.6) | 23 (10.7) | 0.721 | | Hypertension, (%) | 87 (40.5) | 86 (40.0) | 96 (44.4) | 93 (43.3) | 0.746 | | History of DM 1, (%) | 2 (0.9) | 2 (0.9) | 0 (0.0) | 4 (1.9) | 0.256 | | History of DM 2, (%) | 38 (17.7) | 24 (11.2) | 34 (15.7) | 15 (7.0) | 0.004 | | STEMI, (%) | 30 (14.0) | 35 (16.3) | 31 (14.4) | 32 (14.9) | 0.913 | | TnT release, (%) | 117 (54.4) | 115 (53.5) | 120 (55.6) | 115 (53.5) | 0.969 | | eGFR (μmol L−1) | 63.5 ± 22.1 | 61.7 ± 20.8 | 62.9 ± 20.2 | 63.0 ± 20.3 | 0.834 | | Cholesterol/Statin, (%) | 104 (48.4) | 105 (48.8) | 109 (50.5) | 107 (49.8) | 0.973 | | Beta-blocker, (%) | 81 (37.7) | 78 (36.3) | 77 (35.6) | 73 (34.0) | 0.881 | | Known CHD, (%) | 140 (65.1) | 132 (61.4) | 142 (65.7) | 129 (60.0) | 0.537 | | BMI (kg/m2) | 25.7 ± 4.4 | 26.3 ± 4.7 | 25.7 ± 4.2 | 25.0 ± 3.7 | 0.024 | | BNP quartiles | | | | | 0.222 | | Q1 | 47 (22.8) | 52 (24.8) | 44 (21.4) | 64 (31.7) | | | Q2 | 50 (24.3) | 50 (23.8) | 60 (29.1) | 44 (21.8) | | | Q3 | 48 (23.3) | 53 (25.2) | 54 (26.2) | 53 (26.2) | | | Q4 | 61 (29.6) | 55 (26.2) | 48 (23.3) | 41 (20.3) | | | hsCRP quartiles | | | | | 0.910 | | Q1 | 51 (23.7) | 52 (24.2) | 53 (24.5) | 61 (28.4) | | | Q2 | 49 (22.8) | 50 (23.3) | 56 (25.9) | 57 (26.5) | | | Q3 | 57 (26.5) | 57 (26.5) | 53 (24.5) | 50 (23.3) | | | Q4 | 58 (27.0) | 56 (26.0) | 54 (25.0) | 47 (21.9) | |
|
|
Mean ± SD.
SD, standard deviation; 25(OH)D, 25-hydroxyvitamin D; CHF, congestive heart failure; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; DM, diabetes mellitus; STEMI, ST-elevation myocardial infarction; TnT, troponin T; eGFR, estimated glomerular filtration rate; CHD, coronary heart disease; BMI, body mass index; BNP, B-type natriuretic peptide; hsCRP, high sensitivity C-reactive protein.
|
